ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA

Background: Relapsed or refractory (R/R) classic Hodgkin lymphoma (cHL) has a poor outlook with chemotherapy alone (long-term survival 10-20%). In fit patients, non cross-reacting salvage regimens and high dose chemotherapy with autologous stem cell transplant (ASCT) improve 5 year freedom from second failure (FF2F) to 42%. Progressive disease, toxicity of salvage therapy and failure to harvest stem cells are common barriers to ASCT. The most...